Inform HER-2/neu breast cancer test

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved January 1998

Specific Treatments:

breast cancer prediction

Find Related Trials for The Following Conditions

General Information

Inform has been approved for the prediction of breast cancer. It is a gene-based test which identifies the presence or absence of increased copies of the HER-2/neu gene, a gene known to have an increased presence in a particularly aggressive form of breast cancer.

Clinical Results

In studies with early breast cancer patients, 69% of the women who tested positive for the HER-2/neu gene survived five years after surgery compared with 97% of patients with negative test results.